Literature DB >> 9735325

C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells.

L G Sheffield1.   

Abstract

Nontumorigenic human mammary epithelial cells (184.A1 line) were stably transfected with ErbB2 or with Ha-Ras. Transformation with ErbB2, but not ras, resulted in a 5-6 fold increase in c-src activity without affecting c-src content of cells. Similar activation of c-src by ErbB2 was also observed in other non-tumorigenic mammary epithelial cells, including the human line MCF10A and the mouse line NMuMG. Activation of c-src appeared to be dependent on active ErbB2 tyrosine kinase, as the ErbB2 inhibitor tyrphostin AG 825 blocked the induction of c-src kinase activity, as well as the ability of transformed cells to grow on soft agar, but not plastic. The src-selective inhibitor PP1 effectively reduced c-src activity, as well as growth of ErbB2-transformed cells on soft agar, but not on plastic. These results indicate that activation of c-src is a consequence of ErbB2 kinase activity in human breast cancer cells overexpressing ErbB2, and that increased activity of c-src may be responsible for attachment-independent growth of the cells. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9735325     DOI: 10.1006/bbrc.1998.9214

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Authors:  Priya Koppikar; Seung-Ho Choi; Ann Marie Egloff; Quan Cai; Shinsuke Suzuki; Maria Freilino; Hiroshi Nozawa; Sufi M Thomas; William E Gooding; Jill M Siegfried; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

Review 2.  Src family kinases and paclitaxel sensitivity.

Authors:  Xiao-Feng Le; Robert C Bast
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

Review 3.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 4.  EGFR may couple moderate alcohol consumption to increased breast cancer risk.

Authors:  Christopher P Mill; Julia A Chester; David J Riese
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-10-05

5.  The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner.

Authors:  S Sean Houshmandi; Ryan J Emnett; Marco Giovannini; David H Gutmann
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

6.  Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells.

Authors:  Luis E Arias-Romero; Sayanti Saha; Olga Villamar-Cruz; Shu-Chin Yip; Stephen P Ethier; Zhong-Yin Zhang; Jonathan Chernoff
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

7.  Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells.

Authors:  Hee Boong Park; Vita Golubovskaya; Lihui Xu; Xihui Yang; Jin Woo Lee; Sean Scully; Rolf Joseph Craven; William G Cance
Journal:  Biochem J       Date:  2004-03-01       Impact factor: 3.857

8.  Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.

Authors:  B N Rexer; A-J L Ham; C Rinehart; S Hill; N de Matos Granja-Ingram; A M González-Angulo; G B Mills; B Dave; J C Chang; D C Liebler; C L Arteaga
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

Review 9.  Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer.

Authors:  J S Biscardi; R C Ishizawar; C M Silva; S J Parsons
Journal:  Breast Cancer Res       Date:  2000-03-07       Impact factor: 6.466

10.  Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.

Authors:  G R Wilson; A Cramer; A Welman; F Knox; R Swindell; H Kawakatsu; R B Clarke; C Dive; N J Bundred
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.